A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative.

DISCLOSURES: The author reports funding from the U.S. Food and Drug Administration to study real-world data approaches to detect generic drug quality issues. There are no further conflicts or disclosures.